Dana Investment Advisors Inc. Acquires 1,452 Shares of STERIS plc (NYSE:STE)

Dana Investment Advisors Inc. grew its holdings in STERIS plc (NYSE:STE - Free Report) by 84.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,174 shares of the medical equipment provider's stock after purchasing an additional 1,452 shares during the period. Dana Investment Advisors Inc.'s holdings in STERIS were worth $652,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Ashton Thomas Securities LLC purchased a new position in shares of STERIS during the third quarter worth about $25,000. Human Investing LLC bought a new stake in STERIS in the 4th quarter worth approximately $31,000. Anfield Capital Management LLC boosted its stake in STERIS by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after buying an additional 91 shares in the last quarter. Central Pacific Bank Trust Division grew its position in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 76 shares during the last quarter. Finally, Manchester Capital Management LLC grew its position in STERIS by 182.7% during the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 137 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

STE has been the topic of a number of recent research reports. Piper Sandler raised their price objective on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. JMP Securities restated a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Finally, Stephens reaffirmed an "overweight" rating and issued a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.

Remove Ads

STERIS Trading Down 1.6 %

NYSE:STE traded down $3.70 during mid-day trading on Wednesday, reaching $224.36. 402,536 shares of the company's stock traded hands, compared to its average volume of 526,585. The company has a 50 day moving average price of $217.94 and a 200-day moving average price of $222.62. The firm has a market capitalization of $22.04 billion, a price-to-earnings ratio of 47.64 and a beta of 0.92. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. STERIS plc has a 12-month low of $197.82 and a 12-month high of $248.24.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Thursday, February 20th. STERIS's payout ratio is presently 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.